주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
European Lung Cancer Congress 2025 (ELCC 2025)
26 March - 29 March, 2025, France
EGFR-related skin AE rates drop with COCOON regimen
2025-06-30
Interim data from the phase II COCOON trial demonstrate the potential of the COCOON dermatologic management (DM) regimen to significantly reduce the incidence and severity of dermatologic adverse events (dAEs) tied to amivantamab plus lazertinib treatment in patients with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).
First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression
2025-06-30
First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.
KRAS-mutant advanced NSCLC responds to fulzerasib?cetuximab combo
2025-06-30
First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.
MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC
2025-06-30
In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
Neoadjuvant chemotherapy plus durvalumab improves survival in resectable NSCLC
2025-06-30
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.
Patient-reported outcome data support perioperative durvalumab for operable NSCLC
2025-06-30
In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.
SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
2025-06-30
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
